Knowledge, Attitudes, and Practices Among Patients with Systemic Lupus Erythematosus Toward Disease Management and Biologic Therapy
Xiaojing Liu,You Song,Limin Wan,Rong Du
DOI: https://doi.org/10.2147/jmdh.s444619
2024-03-02
Journal of Multidisciplinary Healthcare
Abstract:Xiaojing Liu, &ast You Song, &ast Limin Wan, Rong Du Department of Rheumatology and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China &astThese authors contributed equally to this work Correspondence: Rong Du, Department of Rheumatology and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China, Email Background: This study aims to investigate the knowledge, attitudes, and practices (KAP) among patients with systemic lupus erythematosus (SLE) toward disease management and biologic therapy. Methods: This cross-sectional study was conducted between April 20, 2023, and May 5, 2023, among patients with SLE at Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology. A self-designed questionnaire was developed to collect demographic information of SLE patients and assess their KAP. Results: A total of 463 SLE patients participated. The mean scores for knowledge, attitudes, and practices were 8.52 ± 2.36 (possible range: 0– 11), 39.40 ± 3.38 (possible range: 11– 55), and 27.10 ± 6.29 (possible range: 8– 40), respectively. The path analysis demonstrated a significant and positive association between knowledge and attitudes, as indicated by a path coefficient of 0.455 (p < 0.001), and a significant and positive relationship between knowledge and practices, with a path coefficient of 0.709 (p < 0.001). Conclusion: Patients with SLE exhibited insufficient knowledge, negative attitudes, and poor practices. Keywords: knowledge, attitudes, practices, systemic lupus erythematosus, biologic therapy, cross-sectional study Systemic lupus erythematosus (SLE), a chronic, systemic autoimmune disease, is characterized by the presence of numerous autoantibodies in the bloodstream and multi-organ involvement. With alternating periods of remission and relapse, SLE poses a significant chronic health threat. The majority of SLE cases in China occur in young individuals. Data from the Chinese SLE Treatment and Research group (CSTAR) demonstrate an average onset age of 30.7 years, with a female-to-male ratio of 12:1. 1,2 Conventional approaches for SLE involve glucocorticoids and immunosuppressive agents. However, their long-term use presents challenges due to toxic side effects. In light of advancing knowledge concerning the molecular mechanisms underlying autoimmune diseases, novel therapeutic targets have been identified, leading to the development of biologic therapy that selectively intervenes in specific targets. Biologic therapy not only demonstrates comparable or superior efficacy to traditional therapies but also exhibits fewer adverse reactions and faster onset of action. 3 Despite these advantages, the high cost of biologic therapy poses a considerable financial burden for SLE patients, who already face economic challenges associated with their condition. SLE substantially impacts patients' lives, work, and social activities, often resulting in limited physical capabilities and job loss. A cross-sectional study evaluating the employment status of Chinese SLE patients, which included 105 patients who were employed at the time of their SLE diagnosis, demonstrated that 39 (37%) of these patients lost their ability to work due to SLE, with this occurring after an average disease duration of 10.0 ± 6.1 years. 4 Another contributing factor to the limited adoption of biologic therapy is the insufficient awareness among SLE patients toward disease management and available treatment options. Several surveys investigating disease awareness among SLE patients indicate insufficient knowledge, limited access to disease-related information, and a notable lack of awareness regarding treatment medications. 5,6 Both the economic burden faced by SLE patients and their limited understanding of disease management have a substantial impact on their attitudes, practices, and willingness to opt for biologic therapy as a treatment, as well as their active involvement in disease management, consequently impacting the prognosis of SLE patients. The Knowledge, Attitude, Practice model (abbreviated as KAP) is one of the most commonly used models to explain how an individual's knowledge and beliefs influence changes in health behavior and is one of the models for changing human health-related behaviors. It divides the process of behavior change into three continuous stages: acquiring knowledge, developing beliefs, and forming behaviors. 7,8 Hence, it is crucial to explore KAP of Chinese SLE patients concerning disease management and the utilization of biologic therapy. Th -Abstract Truncated-
health care sciences & services